Drugs / e-ATG
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03663933 Background | Sep 2018 → Apr 2025 overdue | T-cell immunodeficiency, autoimmune lymphoproliferative syndrome, common variable immunodeficiency | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | e-ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03663933 ↗ |
| Route | Intravenous | “Equine anti-thymocyte globulin (e-ATG) 40 mg/kg intravenous (IV) once daily for days -14 and -13.” NCT03663933 ↗ |